Plant Name: Ligustrum japonicus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; FFAR1; FFAR4; | |
| PTPN1; PTPN2; ACP1; PTPRF; CDC25B; | |
| RECQL; PLA2G1B; FAAH; TERT; HPGD; HSD11B1; AKR1B10; ALOX15; POLB; | |
| PRKCA; | |
| PPARA; PPARD; PPARG; | |
| RORC; | |
| NR1H4; | |
| LMNA; FABP3; FABP5; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 5.382E-09 | 1.729E-05 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 8.157E-09 | 1.822E-05 | FFAR4, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.400E-08 | 2.666E-05 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 1.929E-07 | 2.471E-04 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 7.505E-07 | 7.106E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.093E-06 | 1.341E-03 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0044242; cellular lipid catabolic process | 3.072E-06 | 1.760E-03 | AKR1B10, FAAH, FABP3, FABP5, PPARD |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.250E-06 | 1.814E-03 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 3.805E-06 | 1.973E-03 | FABP3, FFAR1, NR1H4, PPARG |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 5.222E-06 | 2.472E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 5.222E-06 | 2.472E-03 | GPBAR1, NR1H4 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.490E-06 | 3.198E-03 | CDC25B, FABP5, HPGD, LMNA, NR1H4, POLB, PPARA, PPARD, PPARG, PRKCA, PTPN2, RECQL, RORC, TERT |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.044E-05 | 4.058E-03 | PTPN1, PTPN2 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.738E-05 | 5.734E-03 | PPARA, PPARG |
| MF | Unclassified; | GO:0004872; receptor activity | 1.776E-05 | 5.773E-03 | FFAR1, FFAR4, GPBAR1, HPGD, NR1H4, PPARA, PPARD, PPARG, PTPRF, RORC |
| BP | GO:0008152; metabolic process | GO:0045834; positive regulation of lipid metabolic process | 2.100E-05 | 6.667E-03 | FABP3, NR1H4, PPARA, PPARG |
| BP | GO:0008283; cell proliferation | GO:0048660; regulation of smooth muscle cell proliferation | 2.456E-05 | 6.850E-03 | HPGD, PPARD, PPARG, TERT |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 2.605E-05 | 6.850E-03 | PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0060336; negative regulation of interferon-gamma-mediated signaling pathway | 2.605E-05 | 6.850E-03 | PPARG, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 2.605E-05 | 6.850E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 2.605E-05 | 6.850E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 2.605E-05 | 6.850E-03 | FABP3, PPARG |
| BP | GO:0009987; cellular process | GO:0070372; regulation of ERK1 and ERK2 cascade | 2.853E-05 | 7.225E-03 | ALOX15, FFAR4, PRKCA, PTPN1, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 3.395E-05 | 8.213E-03 | FABP3, PLA2G1B, PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 3.828E-05 | 9.060E-03 | NR1H4, PTPN1, PTPN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.622E-08 | 2.701E-06 | FABP3; FABP5; PPARG; PPARA; PPARD |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.189E-04 | 6.124E-03 | PTPN1; ACP1; PTPRF |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.737E-04 | 1.283E-02 | PTPN1; PPARA; PTPRF |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.457E-04 | 1.663E-02 | PLA2G1B; ALOX15 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; FFAR1; PPARD; PPARG; PPARG |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| C00-D49: Neoplasms | Cancer | C00-C96 | CDC25B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; PPARD; PPARD; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; FFAR1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B; FAAH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PLA2G1B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; FFAR1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PPARG; PPARG |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT |
| NA: NA | Dyslipidemia | NA | PPARD |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |